secwatch.observer — SEC 8-K summary
======================================

Issuer:     GRI Bio, Inc. (GRI)
CIK:        0001824293
Form:       8-K
Filed at:   2023-08-23T23:59:59+00:00
Accession:  0001824293-23-000159
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.45
Item codes: 1.01, 2.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GRI Bio sells ADAIR asset to Aardvark for $250k upfront, up to $80M milestones
------------------------------------------------------------------------------

- Sold ADAIR abuse-deterrent amphetamine formulation to Aardvark Therapeutics for $250k upfront plus potential milestones.
- ADAIR failed to meet FDA approval threshold in most recent clinical trial for ADHD/narcolepsy.
- Aardvark plans to combine ADAIR with its ARD-101 technology to boost deterrent effect.
- GRI Bio retains rights in Europe/UK via existing Medice license; proceeds allow focus on NKT cell modulators.
- Up to ~$80 million in total development and commercial milestones if Aardvark achieves targets.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1824293/000182429323000159/0001824293-23-000159-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1824293/000182429323000159/val-20230822.htm
  HTML page:      https://secwatch.observer/filing/0001824293-23-000159

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer